scPharmaceuticals (SCPH) Competitors

scPharmaceuticals (NASDAQ:SCPH) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, community ranking, earnings and dividends.

Which has more volatility & risk, SCPH or EOLS?

scPharmaceuticals has a beta of 0.14, suggesting that its stock price is 86% less volatile than the S&P 500. Comparatively, Evolus has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500.

Which has preferable earnings and valuation, SCPH or EOLS?

scPharmaceuticals has higher earnings, but lower revenue than Evolus. Evolus is trading at a lower price-to-earnings ratio than scPharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
scPharmaceuticals	$30.28M	5.90	-$54.81M	-$1.90	-1.88
Evolus	$248.33M	2.83	-$61.69M	-$0.91	-12.21

Is SCPH or EOLS more profitable?

Evolus has a net margin of -22.33% compared to scPharmaceuticals' net margin of -264.60%. scPharmaceuticals' return on equity of -244.93% beat Evolus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
scPharmaceuticals	-264.60%	-244.93%	-68.56%
Evolus	-22.33%	-847.60%	-22.15%

Do institutionals and insiders hold more shares of SCPH or EOLS?

89.5% of scPharmaceuticals shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 5.5% of scPharmaceuticals shares are held by insiders. Comparatively, 6.1% of Evolus shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Does the MarketBeat Community believe in SCPH or EOLS?

Evolus received 192 more outperform votes than scPharmaceuticals when rated by MarketBeat users. Likewise, 72.58% of users gave Evolus an outperform vote while only 66.67% of users gave scPharmaceuticals an outperform vote.

Company	Underperform	Outperform
scPharmaceuticals	Outperform Votes 160 66.67%	Underperform Votes 80 33.33%
Evolus	Outperform Votes 352 72.58%	Underperform Votes 133 27.42%

Do analysts recommend SCPH or EOLS?

scPharmaceuticals presently has a consensus target price of $15.00, suggesting a potential upside of 320.17%. Evolus has a consensus target price of $23.00, suggesting a potential upside of 107.02%. Given scPharmaceuticals' higher probable upside, research analysts plainly believe scPharmaceuticals is more favorable than Evolus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
scPharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Evolus	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to SCPH or EOLS?

In the previous week, Evolus had 3 more articles in the media than scPharmaceuticals. MarketBeat recorded 4 mentions for Evolus and 1 mentions for scPharmaceuticals. Evolus' average media sentiment score of 0.79 beat scPharmaceuticals' score of -0.64 indicating that Evolus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
scPharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Evolus	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Evolus beats scPharmaceuticals on 12 of the 17 factors compared between the two stocks.